Last reviewed · How we verify

Farma de Colombia SA — Portfolio Competitive Intelligence Brief

Farma de Colombia SA pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
GROUP C: Chlorthalidone GROUP C: Chlorthalidone phase 3 Thiazide-like diuretic Sodium-chloride cotransporter (NCC) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eurofarma Laboratorios S.A. · 1 shared drug class
  2. Hospices Civils de Lyon · 1 shared drug class
  3. NHS Greater Glasgow and Clyde · 1 shared drug class
  4. University of North Carolina, Chapel Hill · 1 shared drug class
  5. University of Virginia · 1 shared drug class
  6. VA Office of Research and Development · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Farma de Colombia SA:

Cite this brief

Drug Landscape (2026). Farma de Colombia SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/farma-de-colombia-sa. Accessed 2026-05-17.

Related